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Diverse antiviral IgG effector activities are
predicted by unique biophysical antibody
features
Hao D. Cheng1,2, Karen G. Dowell3, Chris Bailey‑Kellogg3, Brittany A. Goods4,5, J. Christopher Love4,5,
Guido Ferrari6,7, Galit Alter8, Johannes Gach9, Donald N. Forthal9, George K. Lewis10, Kelli Greene6,
Hongmei Gao6, David C. Montefiori6,7 and Margaret E. Ackerman1,2*

Abstract
Background: The critical role of antibody Fc-mediated effector functions in immune defense has been widely
reported in various viral infections. These effector functions confer cellular responses through engagement with
innate immune cells. The precise mechanism(s) by which immunoglobulin G (IgG) Fc domain and cognate receptors
may afford protection are poorly understood, however, in the context of HIV/SHIV infections. Many different in vitro
assays have been developed and utilized to measure effector functions, but the extent to which these assays capture
distinct antibody activities has not been fully elucidated.
Results: In this study, six Fc-mediated effector function assays and two biophysical antibody profiling assays were
performed on a common set of samples from HIV-1 infected and vaccinated subjects. Biophysical antibody profiles
supported robust prediction of diverse IgG effector functions across distinct Fc-mediated effector function assays.
While a number of assays showed correlated activities, supervised machine learning models indicated unique anti‑
body features as primary contributing factors to the associated effector functions. Additional experiments established
the mechanistic relevance of relationships discovered using this unbiased approach.
Conclusions: In sum, this study provides better resolution on the diversity and complexity of effector function
assays, offering a clearer perspective into this family of antibody mechanisms of action to inform future HIV-1 treat‑
ment and vaccination strategies.
Keywords: IgG, Antibody, Effector function, HIV, Vaccine
Background
Passive administration of broadly neutralizing antibodies (bnAb) against HIV-1 has been shown to protect
humanized mice [1], non-human primates (NHP) [2],
and to reduce risk of infection by neutralization-sensitive viral strains in humans [3]. Robust protection conferred by broadly neutralizing antibodies has been widely
*Correspondence: Margaret.e.ackerman@dartmouth.edu
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Full list of author information is available at the end of the article

recognized as the consequence of IgG variable domain
(Fv) interactions with viral epitopes, via multiple mechanisms, including the block of viral attachment [4], inhibition of cell–cell transmission [5], and suppression of
viremia [6]. The crystallizable fragment (Fc) part of the
immunoglobulin (IgG) molecule, however, provides
in vivo anti-viral effects as well, through engagement
of innate immune Fcγ receptors (FcγRs). These activities contribute to bnAb-mediated anti-viral activity in
some [7–10], but not all [11] studies that have looked
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to quantitatively evaluate their contribution, as recently
reviewed [12].
Similarly, increasing evidence from animal models suggests that antibody effector functions also play a critical role in protective vaccine-mediated immunity. These
activities include antibody-dependent phagocytosis [13],
complement-dependent cytotoxicity (CDC) [14], antibody-dependent cellular viral inhibition (ADCVI) [15],
and antibody-dependent cellular cytotoxicity (ADCC)
[16], among others. Correlations between plasma ADCC
activity and challenge resistance or decreased viral load
have been observed in a number of NHP studies [17–20].
Antibody-dependent phagocytosis activity has also been
reported to correlate with protection from infection in a
growing number of preclinical studies [21, 22]. Polyfunctional antibody responses—those exhibiting the ability to
elicit the anti-viral activities of diverse effector cell subsets, have also been reported to correlate with protection in vaccine studies [23]. The most definitive work to
date that these correlations may represent mechanisms
of protection comes from a passive transfer experiment
in which polyfunctional but non-neutralizing antibodies
were shown to protect NHP from SIV infection [24].
In humans, early work demonstrated the enrichment of
ADCC-inducing antibodies in long-term HIV non-progressors [25–34]. Antibodies from HIV elite controllers
have exhibited potentiated viral inhibition, NK activation, phagocytosis and antibody-dependent cellular cytotoxicity [35, 36]. Moreover, immune-escape variants have
been identified on ADCC epitopes, suggesting significant
immune pressure applied from ADCC responses [37],
which has also been supported in animal models [38,
39]. Diverse vaccine regimens have likewise supported a
role of antibodies with potent effector function in accomplishing protection from infection [15]. In the context
of low HIV-specific IgA, ADCC activity was associated
with reduced risk of infection among RV144 HIV-1 vaccine recipients [40]. Additional analyses of this trial have
observed that polyfunctional antibodies were induced
[41]. Antibodies to the V1V2 variable loops [42] that elicited complement deposition [43], and IgG3 antibodies
[44], which show elevated phagocytic activity [45], were
also correlated with reduced risk of infection. Consistent
with recent NHP studies [21, 22], the phagocytic activity of HIV-specific antibodies, along with their binding to
FcγRIIa, was observed to correlate with reduced risk of
infection in a phase 2b trial (HVTN505) of a DNA + rAd5
vaccine expressing Envelope glycoproteins from clades
A, B and C [46]. Excitingly, as in the pox-prime, protein
boost RV144 vaccine, HIV-specific IgG3 responses were
also associated with reduced risk of infection in this vaccine regimen [46].
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While this may be rich evidence base on its face, it
has been built on numerous distinct in vitro effector
function assays developed to evaluate ADCC, ADCP,
ADCVI and CDC activities. These assays differ in terms
of the viral targets—ranging from recombinant antigen,
to cells expressing envelope, to native virus; they differ
in the effector cell populations employed—varying from
purified to mixed populations of primary cells to tumorderived cell lines; and they diverge in terms of activities
read out—consisting of surrogate measures of transcriptional changes, other effector cell phenotypes, or direct
cytolytic or virus inhibition activity [47]. Insights into
which assays best reflect processes relevant to outcomes
in vivo principally stand on correlative evidence, and the
antibody features that underlie potent activity in each
assay are poorly resolved. To address this last limitation, we have combined here a high throughput, multiplexed assessment of features of potential importance to
these functions with machine learning in order to define
aspects of the polyclonal antibody response associated
with each of six effector activities previously determined
in a systematic evaluation of four ADCC, one ADCVI,
and two phagocytosis assays performed on a common set
of serum samples from infected and vaccinated individuals [48].

Methods
Antibody samples

As previously described [48], serum antibodies were
purified from a total of 130 subjects, including treated
chronically HIV-1 infected subjects (n = 31), untreated
chronically HIV-1 infected subjects (n = 28), elite controllers (n = 31), who are individuals that are able to suppress HIV-1 replication in the absence of antiretroviral
therapy [49], and recipients of HIV-1 vaccine AIDSVAX
B/B gp120 (n = 20) or placebo (n = 10) [50]. Study subjects’ clinical data are summarized in Additional file 1:
Table S1. Polyclonal serum IgG antibody was separated
from other serum proteins using the Melon gel IgG
purification kit (ThermoFisher Scientific), as previously
described [36]. Studies were approved by appropriate
local Institutional Review Boards and each subject gave
written informed consent.
Effector functional assays

Six IgG effector functional assays were performed in
three different laboratories. A common stock of research
reagents, antigens, and cryopreserved PBMCs were provided to each laboratory unless otherwise specified.
Assay signal to noise was defined as the ratio of the average assay signal observed for serum in HIV-1 infected
subjects to that observed for placebo recipients.
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GTL ADCC

The GranToxiLux (GTL) ADCC assay was performed
as previously reported [51]. CEM.NKRCCR5 target cells
were coated with the recombinant BaL HIV-1 gp120
antigen, followed by the labeling with GranToxiLux
(GTL; Oncolmmunin, Inc), which fluoresces upon
cleavage by Granzyme B (GrB) released by effector cells
present in heterologous PBMC from a healthy donor.
ADCC-mediating antibodies in IgG from serum samples were quantified as the percent of antigen-coated
cells that took up GrB. Peak activity and the area under
the titration curve (AUC) was reported as the assay
readouts.
LUC ADCC

LUC ADCC assay was performed essentially as previous
publication discussed [52, 53]. A vector expressing both
the BaL envelope (HIV BaL.LucR.T2A.ecto/293T/17;
accession number DQ318211) and the Renilla luciferase
reporter gene was used to transfect the CEM.NKRCCR5
cell line. PBMCs were used as effector cells as previously described [54]. IgG was incubated with transfected
cells and PBMCs for 6 h. ADCC-mediating antibodies
induced target cell death and resulted in the reduction of
virus-derived luciferase signal, which was then reported
as the assay readout. Peak activity and the area under the
titration curve (AUC) were reported.
RFADCC

The rapid fluorescent ADCC (RFADCC) was performed
as previously described [16]. Briefly, the CEM-NKRCCR5
T cell line was labeled with intracellular Carboxyfluorescein succinimidyl ester (CFSE), orange fluorescent
dye PKH26, and recombinant SF162 gp120 protein. NK
cells enriched from healthy donor blood with RosetteSep
(Stem Cell Technologies) were used as effector cells. IgG
was incubated with target cells and NK cells for 4 h at
37’C. The proportion of PKH26 + /CFSE- cells was determined by the flow cytometry and reported.
BVADCC

The bound virion ADCC (BVADCC) was performed as
previously reported [55, 56]. In brief, the CEM-NKRCCR5 + T cell line was labeled with intracellular Carboxyfluorescein succinimidyl ester (CFSE), membrane
orange fluorescent dye PKH26, and spinoculated with
entry competent but replication-defective AT-2 BaL
virions (Dr. Jeff Lifson, FCRC, NIH) [57–59] at 12 °C
followed by incubation with serum IgG for 3 h at 37 °C.
Dual dye loss of the target cells was recorded by the flow
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cytometry [16]. Peak activity and the area under the titration curve (AUC) were reported.
ADCVI

The antibody-dependent cell-mediated virus inhibition
(ADCVI) assay was performed as previously reported
[27]. ADCVI measures the change of p24 production in
the presence of antibody and FcyR-bearing effector cells.
Briefly, antibody was incubated with HIV-infected CEMNKRCCR5 cells and fresh PBMCs for 7 days at 37 °C. The
average percent decrease of p24 produced by infected
cells was measured by p24 ELISA and defined as ADCVI
Activity.
Virion phagocytosis

Phagocytosis was performed as previously described
[60]. In brief, serum IgG was incubated with FITClabeled HIV-1 US657 (GenBank U04908), followed by
the addition of THP-1 effector cells. FITC-labeled virus
internalized by effector cells were identified by flow
cytometry. The percentage of FITC + cells was multiplied
by the corresponding fluorescent intensity and reported
as the assay readout. The assay background, determined
by calculating the FITC + cells in the absence of Envspecific antibody, was subtracted from the signals. The
average readout of replicates was reported as an assay
summary measure. Although phagocytosis assays using
FITC-labeled virus may be useful for assessing Fc-FcγR
interactions, FITC has been shown to aggregate virions
independently of antibody, raising some questions as to
physiological relevance of this assay [61].
IgG titering antigen array assay

As previously described [62], a panel of HIV-1 antigens
(Additional file 1: Table S2) was printed onto glass slides
in triplicate, followed by incubation with blocking reagents. IgG was diluted in a ratio between 1:100 and 1:500
and then incubated with the array. Arrays were blocked
again and washed thoroughly before labeling with fluorescent Goat Anti-human IgG detection antibody. The
arrays were then detected by a GenePix 4200Al (Molecular Devices) and analyzed by GenePix Pro 6.0 (Molecular Devices). The median fluorescence intensity (MFI) of
each spot was recorded, and the average of the triplicates
was reported as assay summary measure.
Fc array

A customized multiplexed microsphere assay to define
the characteristics of both Fv and Fc domains of purified
serum antibody samples was conducted as previously
described method [63]. Briefly, recombinant protein
antigens (Additional file 1: Table S2) were covalently
coupled to fluorescently-coded magnetic microspheres,
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which were incubated with dilute antibody to permit
antigen binding, followed by washing and characterization of Fc domains using fluorescent detection reagents
that included Fc receptor (FcR) tetramers, lectins, and
secondary reagents (Additional file 1: Table S2) to identify total antibody isotypes and IgG subclasses. Data was
acquired on a Bio-plex array reader (FlexMap 3D, BioPlex Manager 5.0, Bio-Rad). The net median fluorescence
intensity (MFI) was reported.

under the same settings using the same input features
but permuted outputs, and this process was repeated for
250 iterations. The average prediction accuracy for both
permuted outputs, and for influenza-based inputs was
compared to the original predictions using an unpaired
two-sided student t test corrected for multiple hypothesis
testing by controlling the false discovery rate to 1% using
the two-stage step-up procedure of Benjamini, Krieger,
and Yekutieli [70].

Data visualizations

Results
Purified polyclonal antibodies collected from chronically infected subjects on (treated) and off (untreated)
anti-retroviral therapy, elite controllers, and VAX004
HIV-1 recombinant gp120 vaccine and placebo recipients
were previously tested in six different IgG effector function assays conducted by different labs [48]. These assays
include four antibody-dependent cellular cytotoxicity
assays (GTL, LUC, RFADCC, and BVADCC), one antibody-dependent phagocytosis (Phagocytosis) assay and
one antibody-dependent cell-mediated virus inhibition
(ADCVI) assay. As previously reported, serum IgG from
HIV-infected subjects generally showed a more robust
capacity to induce diverse effector functions than that
from vaccine recipients, who in turn showed elevated
responses as compared to placebo recipients (Fig. 1A). A
subset of HIV-infected subjects showed elevated activity
across multiple ADCC assays (RFADCC, BVADCC, and
GTL). Different subsets of infected subjects showed high
activity in ADCVI and Phagocytosis assays. As previously reported [71], serum IgG from a subset of the elite
controllers exhibited a polyfunctional profile.
The same set of purified IgG samples were also tested
in two different biophysical binding assays: a microarray
approach used to detect IgG responses to a set of printed
antigens, and a multiplexed bead array used to define
antibody isotypes, subclasses, and FcγR- and lectin-ligation profiles across diverse antigen types and viral strains.
To gain a sense of the specific features that differed
between subjects and groups, HIV-specific response data
from the bead array was visualized in clustered heatmap form (Fig. 1B). Whereas responses among placebo
recipients were uniformly low across measurements,
HIV-specific antibody responses among vaccine recipients and infected subjects varied considerably. Robust
induction of IgG4 rarely resulted from natural infection, but was widely observed among VAX004 vaccine
recipients. A subset of subjects exhibited antibodies with
elevated ability to bind to lectins. This characteristic was
not well correlated with other measures of the antibody
response, suggesting it represents a unique distinction,
the precise origin and functional consequences of which
are unknown. Whereas gp41-specific responses were

HIV-specific antibody features defined by the Fc Array
were centered and scaled. Heatmap analysis of relationships between subjects and among antibody features
defined by the Fc Array and antibody effector functions
was performed using the heatmap.2 function [64] in R
3.3.1 [65]. Similarities and differences in overall HIV-specific antibody response profiles defined by the Fc Array
were defined by Uniform Manifold Approximation and
Projection (UMAP) analysis using with the “UMAP”
package [66, 67] in R.4.0.4 with default “naïve” method
settings. For each subject, the two embedding coordinates were plotted using Graphpad Prism.
Modeling antibody functions

Effector function data collected from HIV-1 infected subjects (elite controllers, and chronically infected subjects
on or off therapy) were predicted by biophysical data
using HIV specific antigens (gp140, gp120, gp41, nonenvelope antigens and assessment of total serum IgG,
IgA, and IgM) using a regularized random forest (RRF)
tree algorithm [68]. Decision trees (2000) were trained to
minimize regularized mean squared error and evaluated
in the setting of fivefold cross-validation with the coefficient of regularization set at 0.8. Prediction accuracy was
computed as the Pearson correlation coefficient between
mean predicted values and experimentally observed values. Contributions of individual biophysical antibody features to prediction of functional activities were evaluated
by defining the percent increase in mean square error (%
Increase MSE) when individual features were permuted.
Features with larger values represent those with greater
importance/lower redundancy.
Model robustness was evaluated by comparison of
performance of models trained with the experimental effector function data to those trained on permuted
data [69], or with influenza-specific antibody response
data. Influenza-specific antibody features were selected
for use in this control as like HIV, influenza virus demonstrates a high level of antigenic diversity and all subjects were expected to be seropositive. In permutation
tests, the model’s output values (observed effector function) were randomized and RRF models were learned
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Fig. 1 Functional and phenotypic profiles of serum antibodies. A Heatmap of antibody effector functions. Each column represents a specific
measured effector function, and each row represents an individual subject, with subject groups indicated by the color bar at left. B Heatmap
of HIV-specific antibody features. Each column represents a specific measured antibody feature, and each row represents an individual subject.
Subject group is indicated by the vertical color bar and antibody Fv and Fc features by the two horizontal color bars. Several clusters of measures
with conserved Fv specificity or Fc characteristics are labeled. Centered and scaled response magnitudes are plotted with high responses in red,
low responses in blue, and median responses in white. Dendrograms indicate the hierarchical clustering of subjects and response measurements.
C UMAP biplots representing the response profiles for each subject, colored by group. UMAP1 and UMAP2 are two calculated values representing
variability of the input data

relatively similar in magnitude across infected subjects,
responses to gp120 and gp140 showed a considerably
greater degree of variability. Robust IgG2 responses were
rare, and the overall magnitude of IgG antibodies was
similar to IgG1 levels and antibody FcγR-binding activity. Antibodies to internal proteins, including p24, nef,
integrase, and others, were also observed among infected
subjects.
To better represent these complex profiles graphically,
dimensionality reduction by unsupervised UMAP analysis was performed across features specific to domains of
HIV-1 envelope relevant to both vaccine and infection
cohorts (gp120 and gp140 only) (Fig. 1C). Whereas placebo recipients were relatively tightly clustered, other
groups showed greater spread in the distribution of subjects. Antibody profiles from VAX004 recipients were
clearly distinct from those observed among infected
subjects. Whether treated or untreated with antiviral
therapy, chronically infected subjects fell in overlapping regions of the biplot, with elite controllers appearing somewhat shifted toward the lower right edge of this
distribution.

The varying antibody responses observed among
groups and between individuals provided the opportunity to attempt to define which antibody features
were associated with each antibody effector function
among HIV-infected subjects. To accomplish this goal,
a supervised RRF machine learning model was trained
to predict measured effector functions using IgG biophysical measurements. Predictive performance in the
setting of fivefold cross-validation was evaluated across
20 replicates. Whereas models trained on actual data
achieved robust prediction, defined as the degree of
correlation between observed and predicted activity,
models trained on permuted data had no predictive
value (Fig. 2A). Similarly, when influenza rather than
HIV-1 antibody features were used to train the model,
accuracy was significantly degraded, most often to that
expected at random (Fig. 2B). While all six IgG effector
functions were robustly predicted, model accuracy varied considerably. This variation was strongly associated
with the signal to noise profiles inherent to each assay
in this data set (Fig. 2C).
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Fig. 2 IgG effector functions are robustly predicted by HIV-specific antibody biophysical features. A Correlation coefficients between observed
values and predicted values resulting from models learned from actual (blue) and permuted (gray) data when HIV-specific antibody biophysical
features were used to predict effector functions via a regularized random forest tree model in the setting of repeated cross-validation. Bars and
whiskers denote the mean and standard deviation. B Accuracy of models learned from HIV-specific antibody features (blue) as compared to
influenza-specific antibody features (red). Statistical significance was defined by t-test adjusted for multiple hypothesis testing (***p < 0.001). C.
Scatterplot of prediction quality (correlation coefficient) and assay signal to noise ratio. Spearman correlation coefficient and statistical significance
reported in inset

The degree of agreement between predicted and
actual activity in each assay for each HIV-infected subject group suggested that, in general, models predicted
activity among each group equivalently well (Fig. 3). Having established robust predictive performance across
assays and subject groups, we next sought to define the
features supporting each model (Fig. 4). The relative
importance of contributing features, whether they represented a strictly quantitative (IgG titer) or qualitative
(Ig subclasses or Fc domain characteristics) aspect of the
humoral response, was defined for each function. Across
effector assays, distinctions in the antigen-specificity and
Fc domain characteristics relevant to each activity were
readily apparent.
GTL and BVADCC assays were the most accurately
predicted, and both aim to measure antibody-mediated
cellular cytotoxicity. While they were among the most
highly correlated pairs of assays, the major supporting
features turned out to be very different. For GTL assay
activity, gp120-specific antibody ligation of FcγRIII features were primary supporting features, consistent with
the reliance of this assay on gp120-coated target cells,
and NK cells as effectors. In contrast, a broader diversity
of envelope-specific antibody ligation of FcγRII contributed primarily to the prediction of BVADCC results, and
only three FcγRIII features were selected among the top
30 features. In terms of antigen recognition, given the use
of inactivated virions in this assay, contributions from
gp41- and gp140-specific antibodies are likely to have
direct mechanistic relevance. In terms of Fc domain characteristics, a strong dependence on FcγRII, more widely
associated with phagocytosis and a diversity of effector
cells, was noted. Interestingly, subsequent experiments

have demonstrated that this assay, which employs unfractionated PBMCs, actually primarily assesses activity
mediated by monocytes, and which is mechanistically
dependent on FcγRII [72, 73].
Though not predicted as well as these other ADCC
assays, models of RFADCC assay activity showed a strong
dependence on FcγRIII, consistent with the use of purified NK cells as effectors, and its readout of cell permeabilization dependent on GrB activity driven by FcγRIII
ligation. One attribute common to each of these assays is
their strong reliance on the measures of antibody quality (FcR-related features), as compared to measures of
response magnitude alone (anti-human IgG detection
reagents), indicating that titer-related measurements
were less important than Fc-specific measurements in
predicting these functions.
For ADCVI and phagocytosis assays, p24-specific
antibodies were major contributing features. While
both assays evaluated responses in the context of replication-competent virus, meaning that p24 was present,
it is not clear how a mechanistic role for p24-specific
antibodies in restricting viral outgrowth (ADCVI)
or driving phagocytosis (fluorescent virion uptake)
might be mediated. For ADCVI, which showed a clear
degradation in model accuracy when p24 features
were omitted (RP = 0.55 versus 0.47 without p24 features, p < 0.05), one possibility raised to by this model
is that p24-specific antibodies present in each sample
may interfere with the p24 quantitation that serves as
the measure of virus replication read out by the assay.
This possibility does not exist for the phagocytosis
assay, which does not involve p24 quantitation, and for
which omission of p24 features still resulted in a small
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Fig. 3 IgG effector functions predicted by IgG biophysical features in infected subjects. Scatterplots depicting the degree of correlation between
of predictions of each effector function and observed activity for each HIV-infected subject. Subjects are colored by treatment and controller status.
Inset reports Pearson correlation coefficients (RP) and statistical significance (**p < 0.01, ***p < 0.001). Colored lines indicate the best fit for each
subject group

but statistically significantly reduction in accuracy
(RP = 0.43 versus 0.39 without p24 features, p = 0.10).
Interestingly, and unlike other functions, model performance for phagocytosis was superior among elite
controllers (elite controllers 
RP = 0.66, p = 0.00006;
chronic treated RP = 0.06, p = 0.05; chronic untreated
RP = 0.16, p = 0.4), who are known to exhibit higher
levels of p24-specific antibodies [74, 75] as compared
to chronically infected subject groups. Overall, while
direct mechanistic contributions cannot be determined
without further experiment, the data driven approach
employed linked the otherwise unrelated observations
of better ADCVI activity observed in elite controllers [36] and long term non-progressors [25] and their

elevated p24-specific antibody levels [74, 75]. Coupled
to observations related p24-specific responses to protection made in the setting of protective vaccines [76],
these results suggest a potential avenue for further
mechanistic evaluation [77].
Lastly, led by a titer measurement (IgG specific to
gp120 CM), a number of envelope-specific FcγRIII
features contribute to predictions in the LUC assay.
Intriguingly, despite the use of IgA depleted samples, a
number of IgA features, including responses specific to
internal proteins such as Nef and Integrase also made
contributions. While mechanistic contributions cannot
be excluded, interpretation of model features must also
consider assay reproducibility and model performance
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Fig. 4 Antibody features contributing to prediction of each function. Bar chart depicts the identity and extent of contribution of the top 30
biophysical measurements in models of each effector function. Feature contributions are reported as the percent increase in model mean squared
error (MSE), which quantifies the degradation in model performance when a given feature is permuted. Feature contribution bars are color coded
by feature type: features that characterize the magnitude of total IgG or IgA specific for each antigen are denoted as response magnitude measures
(titer, black), and those that capture IgG subclass, FcγR, and lectin binding profiles are denoted as qualities of the response (quality, blue). Color bars
at left indicate the Fv specificity and Fc characteristic of each feature

quality. The best performing models provided new,
mechanistically relevant insights, and the less well-performing models can be considered to point to both the
limitations of modeling noisy biological data, as well as
to the complexity of antibody effector functions and the
challenges to developing robust in vitro assays for their
assessment.

Discussion
Titers of antigen-specific binding antibodies and neutralizing antibodies are often useful but not entirely sufficient measures to fully explain therapeutic benefit or
vaccine efficacy across a wide variety of pathogens [76,
78–84]. Given the challenges in achieving high titers
of broadly neutralizing antibodies, the discrepancy
between antibody quantity and antibody quality have
posed special challenges to development of an effective
HIV-vaccine. Because both NHP and human immune
correlate studies of experimental vaccines have suggested the importance of antibody effector functions
[46, 85–87], these functions offer an additional means
to restrict infection, thereby motivating interest in

defining how different aspects of antibody quality and
quantity contribute to diverse activities. Potent effector
functions are associated with a set of unique antibody
characteristics, including N-linked glycosylation of the
Fc domain, antibody titer, immune complex size/geometry, epitope specificity, binding avidity, and IgG subclasses [56, 88–92].
While these in vitro antibody activities have shown
associations with protection from HIV-1 infection,
slower progression of AIDS, or lower viral loads in both
humans and nonhuman primates, most of the current
effector function assays utilize pre-defined antigens and
cell lines, which do not fully recapitulate the complexity
of the in vivo immune responses. The variation of individual effector cell populations and genetic polymorphisms in Fc receptors all pose additional challenges to
the interpretation of results in simplified in vitro antibody effector function assays. These and other hostspecific factors add a layer of further functional diversity.
Despite the inability of correlative relationships to provide direct evidence of mechanism of action, it may be
important to apply multiple and orthogonal assays to
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acquire a comprehensive understanding of the spectrum
of possible in-vivo antiviral antibody activities.
Here, to dissect this rich landscape, supervised machine
learning models were trained to predict effector function
among HIV-infected subjects using antibody profiling
data. The two most accurately predicted effector function
assays, GTL, and BVADCC, were highly correlated with
each other, but predicted by a distinct set of response features. In general, these and other functional assays chiefly
relied upon measures of antibody quality (FcγR binding
propensity and IgG subclass) rather than antibody quantity (antigen-specific IgG titer), and exposed the role of
an unanticipated receptor in one of the assays that was
validated experimentally. Collectively, consistent with
prior studies [75, 76, 91, 93], these results emphasize the
value of specific quality attributes of humoral responses
in inducing potent effective effector functions.
While there was considerable diversity in the antibody
profiles among infected subjects, responses in vaccinees
were even more distinct. In particular, IgG4 responses
were strikingly elevated among VAX004 vaccine recipients as compared to responses observed among infected
individuals, as was previously noted for VAX003 [44].
Such profound differences point to the plasticity of the
immune response. Better understanding of how class
switch recombination is regulated has clear value to both
vaccine design and development of novel approaches to
antibody-driven allergic and autoimmune responses.

response characteristics that could be mechanistically
confirmed. While these results do not enable identification of the activities most relevant to antibodymediated protection from HIV infection in vivo, they
offer further insights into the diversity of effector cell
types and associated antibody phenotypes that may
contribute to viral blockade and restriction.

Conclusions
Given the growing number of studies in the past
decade that have revealed the essential role of Fc
and FcγR-mediated effector activities in both animal and human studies [12], coupled to the diversity
of assays used to characterize these activities [47],
we sought to marry previously published results for
a set of cell-based FcγR-mediated effector function
assays [48] to biophysical antibody profiling assays on
a common set of serum samples from HIV infected
and vaccinated individuals. Intrigued by acquiring a
deeper resolution of specific antibody features associated with complementary effector functions, this
study discovered more differences than similarities
among the different assays. By using machine learning methods to relate activity observed in each assay
to underlying characteristics of the humoral response
as defined by two high-throughput, multiplexed profiling assays, we found that assays with good signal to
noise could be robustly predicted from HIV- but not
permuted or influenza-specific antibody profile data.
Further, even among the most highly correlated assays,
predictions were driven by unique combinations of
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